Comparative Study Between -Blockers and Combination of -blockers and Phosphodiestrase 5-Inhibitors in Treatment of Benign Prostatic Hyperplasia

Abstract

enign prostatic hyperplasia (BPH) is defined as the proliferation of prostatic stromal cells, which results in an enlarged prostate gland. As a result, the prostatic urethra is compressed, which restricts the flow of urine from the bladder. BPH is relatively common in men and symptoms can start as early as age 30. By the age of 50, up to 50% of men exhibit histologic evidence of BPH symptoms and these symptoms tend to increase with age. BPH symptoms are generally referred to as "Lower urinary tract symptoms" or LUTS, and these can be subdivided into voiding symptoms and storage symptoms. Voiding symptoms include hesitancy, intermittency, straining, dribbling, and the decreased caliber of the urine stream. Storage symptoms include frequency, urgency, and nocturia. The severity of BPH can be measured by using the International Prostate Symptom Score (IPSS) questionnaire. Variable treatment options are available for treatment of patients with benign prostatic hyperplasia (BPH) ranging from watchful waiting, Pharmacological therapy, minimally invasive to invasive therapy. Pharmacological therapy include, alpha blockers, 5 alpha-reductase inhibitors and phytotherapy. In our analysis the aim of this study is to compare between the effect of alpha blocker (Tamsulosin 0.4 mg once at night) and a combination of alpha blockers (Tamsulosin 0.4 mg once at morning) and PDE5 inhibitors (Sildenafil 25 mg at night) in treatment of benign prostatic hyperplasia patients through evaluation of IPSS and post-voiding residual urine and uroflometry before and after treatment.